Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine–threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600–mutant metastatic melanoma in a phase 1 trial and improved...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Sosman, Jeffrey A., Kim, Kevin B., Schuchter, Lynn, Gonzalez, Rene, Pavlick, Anna C., Weber, Jeffrey S., McArthur, Grant A., Hutson, Thomas E., Moschos, Stergios J., Flaherty, Keith T., Hersey, Peter, Kefford, Richard, Lawrence, Donald, Puzanov, Igor, Lewis, Karl D., Amaravadi, Ravi K., Chmielowski, Bartosz, Lawrence, H. Jeffrey, Shyr, Yu, Ye, Fei, Li, Jiang, Nolop, Keith B., Lee, Richard J., Joe, Andrew K., Ribas, Antoni
Format: Artigo
Sprog:Inglês
Udgivet: 2012
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3724515/
https://ncbi.nlm.nih.gov/pubmed/22356324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1112302
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker